Search Results - "Pandit-Taskar, Neeta"

Lesion Analysis of ¹⁸F-Metafluorobenzylguanidine PET Imaging in Neuroblastoma.

Authors: Pandit-Taskar, Neeta Basu, Ellen Pirasteh, Ali et al.

Source: Journal of Nuclear Medicine. Oct2025, Vol. 66 Issue 10, p1568-1574. 7p.

Theranostic Intratumoral Convection-Enhanced Delivery of ¹²⁴I-Omburtamab in Patients with Diffuse Intrinsic Pontine Glioma: Pharmacokinetics and Lesion Dosimetry.

Authors: Pandit-Taskar, Neeta Zanzonico, Pat B. Grkovski, Milan et al.

Source: Journal of Nuclear Medicine. Sep2024, Vol. 65 Issue 9, p1364-1370. 7p.

A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer.

Authors: Pandit-Taskar, Neeta O'Donoghue, Joseph A. Chetty, Dushen et al.

Source: Journal of Nuclear Medicine. Jul2024, Vol. 65 Issue 7, p1051-1056. 6p.

¹⁸F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer.

Authors: Cytryn, Samuel L. Pandit-Taskar, Neeta Lumish, Melissa A. et al.

Source: Journal of Nuclear Medicine. May2024, Vol. 65 Issue 5, p722-727. 6p.

Radioimmunoscintigraphy and Pretreatment Dosimetry of ¹³¹I-Omburtamab for Planning Treatment of Leptomeningeal Disease.

Authors: Pandit-Taskar, Neeta Grkovski, Milan Zanzonico, Pat B. et al.

Source: Journal of Nuclear Medicine. Jun2023, Vol. 64 Issue 6, p946-950. 5p.

Phase 1 study of intraventricular ¹³¹I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies.

Authors: Kramer, Kim Pandit-Taskar, Neeta Kushner, Brian H. et al.

Source: Journal of Hematology & Oncology. 11/12/2022, Vol. 15 Issue 1, p1-12. 12p.

Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice.

Authors: Pandit-Taskar, Neeta Iravani, Amir Lee, Dan et al.

Source: Journal of Nuclear Medicine. 2021 Supplement, Vol. 62, p60S-72S. 13p.

First-in-human imaging with ⁸⁹Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting.

Authors: Pandit-Taskar, Neeta Postow, Michael A. Hellmann, Matthew D. et al.

Source: Journal of Nuclear Medicine. Dec2019, Vol. 60 Issue 12, Preceding p1-1. 39p.

Biodistribution and Dosimetry of Intraventricularly Administered 124I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors.

Authors: Pandit-Taskar, Neeta Zanzonico, Pat B. Kramer, Kim et al.

Source: Journal of Nuclear Medicine. Dec2019, Vol. 60 Issue 12, p1-31. 31p. 1 Color Photograph, 1 Diagram, 5 Charts, 2 Graphs.

Biodistribution and radiation dose estimates for ⁶⁸Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors.

Authors: Krebs, Simone Pandit-Taskar, Neeta Reidy, Diane et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Mar2019, Vol. 46 Issue 3, p677-685. 9p. 1 Diagram, 6 Charts, 2 Graphs.

Biodistribution and Dosimetry of ¹⁸F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies.

Authors: Pandit-Taskar, Neeta Zanzonico, Pat Staton, Kevin D. et al.

Source: Journal of Nuclear Medicine. 1/1/2018, Vol. 59 Issue 1, p147-153. 7p. 2 Color Photographs, 2 Charts, 3 Graphs.

Norepinephrine Transporter as a Target for Imaging and Therapy.

Authors: Pandit-Taskar, Neeta Modak, Shakeel

Source: Journal of Nuclear Medicine. 2017 Supplement2, Vol. 58, p39S-53S. 15p. 1 Color Photograph, 2 Black and White Photographs, 1 Diagram, 2 Charts.

First-in-Human Imaging with ⁸⁹Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.

Authors: Pandit-Taskar, Neeta O'Donoghue, Joseph A. Ruan, Shutian et al.

Source: Journal of Nuclear Medicine. Dec2016, Vol. 57 Issue 12, p1858-1864. 7p. 2 Color Photographs, 1 Black and White Photograph, 1 Diagram, 1 Chart, 4 Graphs.

Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging.

Authors: Pandit-Taskar, Neeta Veach, Darren R. Fox, Josef J. et al.

Source: Journal of Nuclear Medicine. 2016 Supplement3, Vol. 57, p73S-78S. 6p. 3 Color Photographs, 1 Black and White Photograph, 1 Diagram, 2 Graphs.

Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.

Authors: Pandit-Taskar, Neeta O'Donoghue, Joseph Beylergil, Volkan et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Nov2014, Vol. 41 Issue 11, p2093-2105. 13p.

ImmunoPET: harnessing antibodies for imaging immune cells.

Authors: Wu, Anna M. Pandit-Taskar, Neeta

Source: Molecular Imaging & Biology. Apr2022, Vol. 24 Issue 2, p181-197. 17p.

Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease.

Authors: Landau, Heather Pandit-Taskar, Neeta Hassoun, Hani et al.

Source: Leukemia & Lymphoma. Feb2012, Vol. 53 Issue 2, p275-281. 7p. 3 Charts, 2 Graphs.

Bone-Seeking Radiopharmaceuticals for Treatment of Osseous Metastases, Part 1: α Therapy with ²²³Ra-Dichloride.

Authors: Pandit-Taskar, Neeta Larson, Steven M. Carrasquillo, Jorge A.

Source: Journal of Nuclear Medicine. Feb2014, Vol. 55 Issue 2, p268-274. 7p. 1 Color Photograph, 2 Diagrams, 5 Charts, 1 Graph.

¹²⁴I-huA33 Antibody PET of Colorectal Cancer.

Authors: Carrasquillo, Jorge A. Pandit-Taskar, Neeta O'Donoghue, Joseph A. et al.

Source: Journal of Nuclear Medicine. Aug2011, Vol. 52 Issue 8, p1173-1180. 8p. 1 Color Photograph, 1 Black and White Photograph, 2 Charts, 1 Graph.

Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer.

Authors: Apolo, Andrea B. Pandit-Taskar, Neeta Morris, Michael J.

Source: Journal of Nuclear Medicine. Dec2008, Vol. 49 Issue 12, p2031-2041. 11p. 1 Diagram, 7 Charts.